Research & Development
Non Small Cell Lung Cancer
Guardant 360 CDx receives approval in Japan for NSCLC
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for select patients with HER2-mutant NSCLC who are eligible for treatment with the antibody drug conjugate Enhertu.
September 7, 2023
Roche’s Alecensa improves survival in postsurgery lung cancer patients in late-phase trial
Roche’s Alecensa has improved disease-free survival in non-small cell lung cancer patients, positioning the Swiss drugmaker to apply to expand the product label.
September 8, 2023
Lunit to present results of AI-based immunotherapy predictive test study at WCLC 2023
Lunit announced the presentation of data from a collaborative study on the use of the Lunit SCOPE IO test to predict immunotherapy treatment outcomes in lung cancer at the 2023 World Conference on Lung Cancer (WCLC 2023).
August 28, 2023
Amoy Diagnostics, AstraZeneca partner on CDx for lung cancer therapy
This agreement is the latest in ongoing collaborations to develop and commercialize AmoyDx assays for companion diagnostic use with AstraZeneca's prostate, breast, and ovarian cancer therapies.
August 16, 2023
ChromaCode starts early-access launch of lung cancer variant test
The test is designed to address diagnostic problems that prevent patients from undergoing timely cancer biomarker testing and receiving targeted therapies.
August 15, 2023
Illumina inks deal to sell Pillar Biosciences’ cancer assays
Pillar, which has partnerships with Beckman Coulter Life Sciences and Labcorp, designed its NSCLC and CRC panel to run on the Illumina MiSeq Dx instrument. The instrument is a next-generation sequencing (NGS) platform for in vitro diagnostic testing.
July 26, 2023
Single-cell RNA sequencing data reveals T cells linked to cancer immunotherapy resistance
Scientists at the University of Texas MD Anderson Cancer Center have provided a new explanation for why checkpoint inhibitors are ineffective in some patients.
May 30, 2023
Cancer patients’ molecular testing, treatment varies across oncology practices in study
Access to molecular testing and targeted therapy for non-small cell lung cancer and colorectal cancer patients varies across oncology practices.
April 28, 2023
Foundation Medicine to collaborate with Bristol Myers Squibb on companion diagnostic for solid tumors
The FoundationOne CDx test would be used in identifying patients likely to respond to treatment with repotrectinib if both the treatment and the test are approved.
April 11, 2023
Foresight Diagnostics, Memorial Sloan Kettering Cancer Center to present study data on MRD monitoring at AACR
In the study, the Foresight Solid Tumor Recurrence test achieved an LOD95 of less than one part per million in the majority of plasma samples analyzed, and was almost twice as sensitive as a first-generation ctDNA MRD approach.
April 4, 2023
AmoyDx PLC Panel gets Japanese approval as companion diagnostic for NSCLC
The AmoyDx PLC Panel has been approved in Japan for the identification of activating alterations in seven driver genes, including RET, to be used in identifying patients whose NSCLC is likely to respond to treatment with selpercatinib.
March 27, 2023
Guardant Health shares rise on Q4 growth in clinical, biopharma testing
For Q4, the firm reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021.
February 24, 2023
Page 1 of 5